Qualigen Therapeutics Inc (QLGN) News

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”...

Form 8-K - Current report

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”...

Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme

CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the...

Form 8-K - Current report

Qualigen to participate in next funding round for NanoSynex

Market size expected to reach $4.7 billion in 2027 CARLSBAD, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement

Carlsbad, CA, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics (NASDAQ: QLGN) (the “Company” or...

Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC...

Form D - Notice of Exempt Offering of Securities

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares

Carlsbad, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the...